Loading…

Role of the ACTH test and estimation of a safe dose for high potency steroids in vitiligo: A prospective randomized study

Topical corticosteroids are used as first line of therapy for vitiligo, although side effects such as adrenal insufficiency are possible. To establish the role of ACTH test before, during, and after treatment with high potency topical steroids; to determine if adrenal insufficiency occurs secondary...

Full description

Saved in:
Bibliographic Details
Published in:Indian Dermatology Online Journal 2014-04, Vol.5 (2), p.117-121
Main Authors: de la Fuente-García, Alberto, Gómez-Flores, Minerva, Mancillas-Adame, Leonardo, Ocampo-Candiani, Jorge, Welsh-Lozano, Oliverio, Pérez, Jesús Zacarías Villarreal, González-González, José Gerardo, Lavalle-González, Fernando
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4051-18fd38b1574f9ac8ad58a72000146d53f4441d99ea0379d1b1b355a5de99fe803
cites
container_end_page 121
container_issue 2
container_start_page 117
container_title Indian Dermatology Online Journal
container_volume 5
creator de la Fuente-García, Alberto
Gómez-Flores, Minerva
Mancillas-Adame, Leonardo
Ocampo-Candiani, Jorge
Welsh-Lozano, Oliverio
Pérez, Jesús Zacarías Villarreal
González-González, José Gerardo
Lavalle-González, Fernando
description Topical corticosteroids are used as first line of therapy for vitiligo, although side effects such as adrenal insufficiency are possible. To establish the role of ACTH test before, during, and after treatment with high potency topical steroids; to determine if adrenal insufficiency occurs secondary to the use of high potency topical steroids in patients with vitiligo and intact cutaneous barrier; and also to determine response to treatment and side effects. Forty-four adults with non-segmental vitiligo affecting 20% or less of the body surface area were included and randomized to receive topical clobetasol propionate 0.05% cream (group 1) or placebo (group 2) for 12 weeks, with a maximum dose of 50 g per week. The placebo group was crossed over after week 6 and started on clobetasol until completion of the study. Serum cortisol levels with the 1 μg ACTH test were determined at baseline and on weeks 6 and 12. No adrenal insufficiency was detected nor statistical significance was achieved when comparing cortisol levels between and within the groups at baseline and weeks 6 and 12. Group 1 had a better response to therapy but with more side effects. Doses of 50 g or less per week of clobetasol during a period of 12 weeks are safe on adult vitiligo patients, although local side effects are possible. Repigmentation rates were incomplete with single steroid therapy, making combined therapy a better option.
doi_str_mv 10.4103/2229-5178.131071
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a5c28c4cfe5e47d1b0d5c8db42123740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A366188231</galeid><doaj_id>oai_doaj_org_article_a5c28c4cfe5e47d1b0d5c8db42123740</doaj_id><sourcerecordid>A366188231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4051-18fd38b1574f9ac8ad58a72000146d53f4441d99ea0379d1b1b355a5de99fe803</originalsourceid><addsrcrecordid>eNptkt1r2zAUxc3YWEvX9z0NwWDsJZk-bXkPgxC2tVAYjO5ZKNKVrWJbmaQE0r9-8pKVBiY9yNx7zg9f6VTVW4KXnGD2iVLaLgRp5JIwghvyorqklJdS3bCX8_epfVFdp_SAy-KtJLx-XV1QLmvccHJZHX6GAVBwKPeAVuv7G5QhZaQni8rpR519mOa-Rkk7QDYkQC5E1PuuR9uQYTIHlDLE4G1CfkJ7n_3gu_AZrdA2hrQFk_0eUCzMMPpHsEW-s4c31SunhwTXp_Oq-vXt6_36ZnH34_vtenW3MBwLsiDSWSY3RDTctdpIbYXUDS3TlFGsYI5zTmzbgsasaS3ZkA0TQgsLbetAYnZV3R65NugHtY1lpnhQQXv1txBip3TM3gygtDBUGm4cCOBNYWErjLQbTgllDZ9ZX46s7W4zgjUw5aiHM-h5Z_K96sJeFS9mjBfAxxMght-7csNq9MnAMOgJwi4pIqiUDauFKNL3R2mny6_5yYVCNLNcrVhdEykpI0W1_I-qbAujN2EC50v9zPDhmaEHPeQ-hWE3v3M6F-Kj0JRHTBHc05gEqzmAak6YmhOmjgEslnfPr-fJ8C9u7A85fdO0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1528873655</pqid></control><display><type>article</type><title>Role of the ACTH test and estimation of a safe dose for high potency steroids in vitiligo: A prospective randomized study</title><source>Open Access: PubMed Central</source><creator>de la Fuente-García, Alberto ; Gómez-Flores, Minerva ; Mancillas-Adame, Leonardo ; Ocampo-Candiani, Jorge ; Welsh-Lozano, Oliverio ; Pérez, Jesús Zacarías Villarreal ; González-González, José Gerardo ; Lavalle-González, Fernando</creator><creatorcontrib>de la Fuente-García, Alberto ; Gómez-Flores, Minerva ; Mancillas-Adame, Leonardo ; Ocampo-Candiani, Jorge ; Welsh-Lozano, Oliverio ; Pérez, Jesús Zacarías Villarreal ; González-González, José Gerardo ; Lavalle-González, Fernando</creatorcontrib><description>Topical corticosteroids are used as first line of therapy for vitiligo, although side effects such as adrenal insufficiency are possible. To establish the role of ACTH test before, during, and after treatment with high potency topical steroids; to determine if adrenal insufficiency occurs secondary to the use of high potency topical steroids in patients with vitiligo and intact cutaneous barrier; and also to determine response to treatment and side effects. Forty-four adults with non-segmental vitiligo affecting 20% or less of the body surface area were included and randomized to receive topical clobetasol propionate 0.05% cream (group 1) or placebo (group 2) for 12 weeks, with a maximum dose of 50 g per week. The placebo group was crossed over after week 6 and started on clobetasol until completion of the study. Serum cortisol levels with the 1 μg ACTH test were determined at baseline and on weeks 6 and 12. No adrenal insufficiency was detected nor statistical significance was achieved when comparing cortisol levels between and within the groups at baseline and weeks 6 and 12. Group 1 had a better response to therapy but with more side effects. Doses of 50 g or less per week of clobetasol during a period of 12 weeks are safe on adult vitiligo patients, although local side effects are possible. Repigmentation rates were incomplete with single steroid therapy, making combined therapy a better option.</description><identifier>ISSN: 2229-5178</identifier><identifier>EISSN: 2249-5673</identifier><identifier>DOI: 10.4103/2229-5178.131071</identifier><identifier>PMID: 24860741</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>ACTH ; Adrenal insufficiency ; Corticosteroids ; cortisol ; Original ; Topical medication ; topical steroids ; vitiligo</subject><ispartof>Indian Dermatology Online Journal, 2014-04, Vol.5 (2), p.117-121</ispartof><rights>COPYRIGHT 2014 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright: © Indian Dermatology Online Journal 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4051-18fd38b1574f9ac8ad58a72000146d53f4441d99ea0379d1b1b355a5de99fe803</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030334/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030334/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24860741$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de la Fuente-García, Alberto</creatorcontrib><creatorcontrib>Gómez-Flores, Minerva</creatorcontrib><creatorcontrib>Mancillas-Adame, Leonardo</creatorcontrib><creatorcontrib>Ocampo-Candiani, Jorge</creatorcontrib><creatorcontrib>Welsh-Lozano, Oliverio</creatorcontrib><creatorcontrib>Pérez, Jesús Zacarías Villarreal</creatorcontrib><creatorcontrib>González-González, José Gerardo</creatorcontrib><creatorcontrib>Lavalle-González, Fernando</creatorcontrib><title>Role of the ACTH test and estimation of a safe dose for high potency steroids in vitiligo: A prospective randomized study</title><title>Indian Dermatology Online Journal</title><addtitle>Indian Dermatol Online J</addtitle><description>Topical corticosteroids are used as first line of therapy for vitiligo, although side effects such as adrenal insufficiency are possible. To establish the role of ACTH test before, during, and after treatment with high potency topical steroids; to determine if adrenal insufficiency occurs secondary to the use of high potency topical steroids in patients with vitiligo and intact cutaneous barrier; and also to determine response to treatment and side effects. Forty-four adults with non-segmental vitiligo affecting 20% or less of the body surface area were included and randomized to receive topical clobetasol propionate 0.05% cream (group 1) or placebo (group 2) for 12 weeks, with a maximum dose of 50 g per week. The placebo group was crossed over after week 6 and started on clobetasol until completion of the study. Serum cortisol levels with the 1 μg ACTH test were determined at baseline and on weeks 6 and 12. No adrenal insufficiency was detected nor statistical significance was achieved when comparing cortisol levels between and within the groups at baseline and weeks 6 and 12. Group 1 had a better response to therapy but with more side effects. Doses of 50 g or less per week of clobetasol during a period of 12 weeks are safe on adult vitiligo patients, although local side effects are possible. Repigmentation rates were incomplete with single steroid therapy, making combined therapy a better option.</description><subject>ACTH</subject><subject>Adrenal insufficiency</subject><subject>Corticosteroids</subject><subject>cortisol</subject><subject>Original</subject><subject>Topical medication</subject><subject>topical steroids</subject><subject>vitiligo</subject><issn>2229-5178</issn><issn>2249-5673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptkt1r2zAUxc3YWEvX9z0NwWDsJZk-bXkPgxC2tVAYjO5ZKNKVrWJbmaQE0r9-8pKVBiY9yNx7zg9f6VTVW4KXnGD2iVLaLgRp5JIwghvyorqklJdS3bCX8_epfVFdp_SAy-KtJLx-XV1QLmvccHJZHX6GAVBwKPeAVuv7G5QhZaQni8rpR519mOa-Rkk7QDYkQC5E1PuuR9uQYTIHlDLE4G1CfkJ7n_3gu_AZrdA2hrQFk_0eUCzMMPpHsEW-s4c31SunhwTXp_Oq-vXt6_36ZnH34_vtenW3MBwLsiDSWSY3RDTctdpIbYXUDS3TlFGsYI5zTmzbgsasaS3ZkA0TQgsLbetAYnZV3R65NugHtY1lpnhQQXv1txBip3TM3gygtDBUGm4cCOBNYWErjLQbTgllDZ9ZX46s7W4zgjUw5aiHM-h5Z_K96sJeFS9mjBfAxxMght-7csNq9MnAMOgJwi4pIqiUDauFKNL3R2mny6_5yYVCNLNcrVhdEykpI0W1_I-qbAujN2EC50v9zPDhmaEHPeQ-hWE3v3M6F-Kj0JRHTBHc05gEqzmAak6YmhOmjgEslnfPr-fJ8C9u7A85fdO0</recordid><startdate>201404</startdate><enddate>201404</enddate><creator>de la Fuente-García, Alberto</creator><creator>Gómez-Flores, Minerva</creator><creator>Mancillas-Adame, Leonardo</creator><creator>Ocampo-Candiani, Jorge</creator><creator>Welsh-Lozano, Oliverio</creator><creator>Pérez, Jesús Zacarías Villarreal</creator><creator>González-González, José Gerardo</creator><creator>Lavalle-González, Fernando</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt Ltd</general><general>Wolters Kluwer Medknow Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>201404</creationdate><title>Role of the ACTH test and estimation of a safe dose for high potency steroids in vitiligo: A prospective randomized study</title><author>de la Fuente-García, Alberto ; Gómez-Flores, Minerva ; Mancillas-Adame, Leonardo ; Ocampo-Candiani, Jorge ; Welsh-Lozano, Oliverio ; Pérez, Jesús Zacarías Villarreal ; González-González, José Gerardo ; Lavalle-González, Fernando</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4051-18fd38b1574f9ac8ad58a72000146d53f4441d99ea0379d1b1b355a5de99fe803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>ACTH</topic><topic>Adrenal insufficiency</topic><topic>Corticosteroids</topic><topic>cortisol</topic><topic>Original</topic><topic>Topical medication</topic><topic>topical steroids</topic><topic>vitiligo</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de la Fuente-García, Alberto</creatorcontrib><creatorcontrib>Gómez-Flores, Minerva</creatorcontrib><creatorcontrib>Mancillas-Adame, Leonardo</creatorcontrib><creatorcontrib>Ocampo-Candiani, Jorge</creatorcontrib><creatorcontrib>Welsh-Lozano, Oliverio</creatorcontrib><creatorcontrib>Pérez, Jesús Zacarías Villarreal</creatorcontrib><creatorcontrib>González-González, José Gerardo</creatorcontrib><creatorcontrib>Lavalle-González, Fernando</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Indian Dermatology Online Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de la Fuente-García, Alberto</au><au>Gómez-Flores, Minerva</au><au>Mancillas-Adame, Leonardo</au><au>Ocampo-Candiani, Jorge</au><au>Welsh-Lozano, Oliverio</au><au>Pérez, Jesús Zacarías Villarreal</au><au>González-González, José Gerardo</au><au>Lavalle-González, Fernando</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of the ACTH test and estimation of a safe dose for high potency steroids in vitiligo: A prospective randomized study</atitle><jtitle>Indian Dermatology Online Journal</jtitle><addtitle>Indian Dermatol Online J</addtitle><date>2014-04</date><risdate>2014</risdate><volume>5</volume><issue>2</issue><spage>117</spage><epage>121</epage><pages>117-121</pages><issn>2229-5178</issn><eissn>2249-5673</eissn><abstract>Topical corticosteroids are used as first line of therapy for vitiligo, although side effects such as adrenal insufficiency are possible. To establish the role of ACTH test before, during, and after treatment with high potency topical steroids; to determine if adrenal insufficiency occurs secondary to the use of high potency topical steroids in patients with vitiligo and intact cutaneous barrier; and also to determine response to treatment and side effects. Forty-four adults with non-segmental vitiligo affecting 20% or less of the body surface area were included and randomized to receive topical clobetasol propionate 0.05% cream (group 1) or placebo (group 2) for 12 weeks, with a maximum dose of 50 g per week. The placebo group was crossed over after week 6 and started on clobetasol until completion of the study. Serum cortisol levels with the 1 μg ACTH test were determined at baseline and on weeks 6 and 12. No adrenal insufficiency was detected nor statistical significance was achieved when comparing cortisol levels between and within the groups at baseline and weeks 6 and 12. Group 1 had a better response to therapy but with more side effects. Doses of 50 g or less per week of clobetasol during a period of 12 weeks are safe on adult vitiligo patients, although local side effects are possible. Repigmentation rates were incomplete with single steroid therapy, making combined therapy a better option.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>24860741</pmid><doi>10.4103/2229-5178.131071</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2229-5178
ispartof Indian Dermatology Online Journal, 2014-04, Vol.5 (2), p.117-121
issn 2229-5178
2249-5673
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a5c28c4cfe5e47d1b0d5c8db42123740
source Open Access: PubMed Central
subjects ACTH
Adrenal insufficiency
Corticosteroids
cortisol
Original
Topical medication
topical steroids
vitiligo
title Role of the ACTH test and estimation of a safe dose for high potency steroids in vitiligo: A prospective randomized study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A27%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20the%20ACTH%20test%20and%20estimation%20of%20a%20safe%20dose%20for%20high%20potency%20steroids%20in%20vitiligo:%20A%20prospective%20randomized%20study&rft.jtitle=Indian%20Dermatology%20Online%20Journal&rft.au=de%20la%20Fuente-Garc%C3%ADa,%20Alberto&rft.date=2014-04&rft.volume=5&rft.issue=2&rft.spage=117&rft.epage=121&rft.pages=117-121&rft.issn=2229-5178&rft.eissn=2249-5673&rft_id=info:doi/10.4103/2229-5178.131071&rft_dat=%3Cgale_doaj_%3EA366188231%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4051-18fd38b1574f9ac8ad58a72000146d53f4441d99ea0379d1b1b355a5de99fe803%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1528873655&rft_id=info:pmid/24860741&rft_galeid=A366188231&rfr_iscdi=true